Welcome to our dedicated page for Silo Pharma news (Ticker: SILO), a resource for investors and traders seeking the latest updates and insights on Silo Pharma stock.
Silo Pharma develops novel therapeutics and drug-delivery systems for stress-induced psychiatric disorders, chronic pain and central nervous system diseases, while also disclosing activity in cryptocurrency treasury and AI infrastructure initiatives. Company news frequently centers on SPC-15, an intranasal serotonin 5-HT4 receptor agonist program for PTSD and anxiety, as well as other pipeline work involving psychedelic-derived and traditional therapeutic approaches.
Recurring updates include patent allowances and applications in key jurisdictions, FDA and federal-policy context for psychedelic medicines, clinical-development planning, and new CNS discovery initiatives such as ibogaine-based approaches for traumatic brain injury. Corporate news also covers common-stock repurchase authorization, equity-financed asset purchases, the QwikAgents AI-agent platform, and cryptocurrency-related software assets.
Silo Pharma, a developmental stage biopharmaceutical company, has secured $4.275 million through Securities Purchase Agreements for its Series C Preferred Stock. The financing involves issuing 4,276 shares and warrants for 14,253,333 shares of common stock with an exercise price of $0.30 per share. The funds will support the development of psychedelic therapeutics for conditions like depression and PTSD. The transaction, expected to close by February 11, 2021, reflects investor confidence in Silo's strategic growth plan.